Rising Protocol Complexity Is Hindering Performance while Driving Up Cost of Clinical Trials, According to the Tufts Center for the Study of Drug Development
17 juil. 2018 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, July 17, 2018 (GLOBE NEWSWIRE) -- Rising protocol complexity is hindering clinical trial performance and efficiency, and helping to drive up the cost of developing new drugs, according to a...
Patent-to-Launch Time for Orphan Drugs is 2.3 Years Longer vs. Other Drugs, According to the Tufts Center for the Study of Drug Development
09 mai 2018 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, May 09, 2018 (GLOBE NEWSWIRE) -- Orphan drug development, which faces special challenges in recruiting sufficient numbers of patients for clinical trials, on average takes 15.1 years to go...
First Comprehensive Clinical Site Initiation Benchmark, Developed by Tufts Center for the Study of Drug Development, Finds Study Startup Is Lengthy and Inefficient
07 mars 2018 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, March 07, 2018 (GLOBE NEWSWIRE) -- The clinical site initiation process—time needed to identify and select sites and begin studies—takes an average of nearly eight months, longer than it did...
eClinical Data Volume and Diversity Pose Increasing Challenges and Delays, According to the Tufts Center for the Study of Drug Development
09 janv. 2018 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, Jan. 09, 2018 (GLOBE NEWSWIRE) -- The growing volume of data collected in clinical trials is contributing to longer development times and posing technical and integration challenges to...
Pharmaceutical Companies Poised to Build Infrastructure to Accommodate Real World Evidence, According to the Tufts Center for the Study of Drug Development
08 nov. 2017 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Nov 8, 2017) - Real world evidence is poised to play a growing role in drug development during the next three years, but the availability and cost of acquiring data...
Cardiovascular Drug Approval Rate in the U.S. Fell as Development Time Rose, According to the Tufts Center for the Study of Drug Development
12 sept. 2017 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 12, 2017) - Although the rate at which investigational drugs received marketing approval in the United States has declined in recent years, the cardiovascular...
Abuse-Deterrent Opioid Development and Uptake Are Tied to Efficacy and Regulatory/Payer Policies, According to the Tufts Center for the Study of Drug Development
13 juil. 2017 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 13, 2017) - Although 10 new opioid products with abuse-deterrent formulations (ADF) have received regulatory approval in the United States, lack of willingness by...
Accelerating Pace of Approvals and a Strong Development Pipeline Indicate Vigorous Growth for New Biotech Products, According to the Tufts Center for the Study of Drug Development
09 mai 2017 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 9, 2017) - Biopharmaceuticals accounted for 35% of all new drug approvals in the United States from 2006 through 2016, and a robust development pipeline suggests that...
Streamlined Development Process for Certain New Drug Applications Is Not Facilitating Shorter Approval Times, According to the Tufts Center for the Study of Drug Development
08 mars 2017 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Mar 8, 2017) - The 505(b)(2) approval pathway for new drug applications in the United States, aimed at avoiding unnecessary duplication of studies performed on a...
Poor Physician and Nurse Engagement Contributes to Low Patient Recruitment Rates, According to the Tufts Center for the Study of Drug Development
11 janv. 2017 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 11, 2017) - Although physicians and nurses are familiar with, and comfortable discussing, clinical trials, they refer a mere fraction of their patients for these...